Striatech Backs ARVO’s Rising Vision Scientist
At Striatech, advancing the future of ophthalmic research is a central commitment. In partnership with the ARVO Foundation for Eye
Read moreAt Striatech, advancing the future of ophthalmic research is a central commitment. In partnership with the ARVO Foundation for Eye
Read moreMerck KGaA is moving forward with the acquisition of SpringWorks Therapeutics, confirming a definitive agreement at $47 per share in
Read moreEli Lilly and Company announced groundbreaking Phase 2 results for its investigational siRNA therapy lepodisiran, which reduced lipoprotein(a) [Lp(a)] levels
Read moreLexicon Pharmaceuticals announced an exclusive worldwide licensing agreement with Novo Nordisk for LX9851, a first-in-class oral non-incretin therapy in development for
Read moreNovartis has received its third U.S. Food and Drug Administration (FDA) approval for Fabhalta® (iptacopan), marking a major milestone as
Read moreAccelerating Immunoassay Development With Automated Storage, Filling and Labeling – Case Study An HTI Automation & Mabtech Case Study The
Read moreThe CTAT Enzymatic Antibody Drug Conjugation Technology -Benefits for Diagnostic Applications and ADC’s for Oncology. A Biosynth Case Study This
Read moreIn a significant move to expand its oncology portfolio, Taiho Pharmaceutical Co., Ltd. has entered a definitive agreement to fully
Read moreA groundbreaking study by Groh et al., recently featured in Nature Communications, delves into the interplay between adaptive immunity and
Read moreDarkAdapt, an advanced extension of the OptoDrum system, enables precise and reproducible studies with dark-adapted rodents. This innovative instrument provides
Read more